Helping an Emerging Manufacturer Gain Top-notch Valuation in a $10B Pharma Acquisition

A clinical-stage biopharmaceutical company pioneering in precision medicine to discover, develop and commercialize targeted therapies for the treatment of rare diseases, was transitioning from an R&D organization into a fully-integrated global pharmaceutical company. The manufacturer approached Blue Fin Group for support in preparing for product commercialization of their first therapeutic candidate in a new drug class for the potential treatment of a rare vascular disease. Learn more about their outcomes by downloading the case study. Download below!